The Microbiome Business & Science Briefing

Reporting on The Latest Microbiome Business & Scientific Developments

TRENDING

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Editor's Choice /Pharma & Human Health

Editor's Choice

Modulating the Preterm Gut Microbiota: An Interview with Dr Lindsay Hall

Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.

BY Microbiome Times · MAY 9, 2019 · 1 MIN READ

Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.

Microbiome Times